Price movement over the last 24 hours
ADMA Biologics Inc vs iShares Self-Driving EV and Tech — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while iShares Self-Driving EV and Tech trades at $36.18. The key difference: iShares Self-Driving EV and Tech is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | IDRV | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $45.48 |
52-Week Low | $7.60 | $31.81 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
IDRV trades at $38.51, up 2.01% today, but technical indicators signal a bearish trend with moving averages showing strong selling pressure. The ETF faces industry headwinds as rising fuel prices boost EV demand globally while US market adoption lags. Recent news highlights competitive threats from Chinese EV makers expanding internationally and regulatory uncertainty around US-China trade policies.
The ETF's outlook is challenged by sector volatility and geopolitical risks, though global EV adoption trends provide long-term growth potential. Key risks include tariff policy changes and slower-than-expected US EV adoption. Investors should monitor quarterly flows and sector performance for directional cues amid mixed technical signals.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →